Hints and tips:
...Ogilvy, which has previously worked with a host of pharma groups including Pfizer and Johnson & Johnson, is launching a business that offers vetted influencers to talk about illnesses and possible solutions...
...wants a pivot in the biotech’s sales strategy for its Covid-19 shot, which is based on traditional vaccine technology, to target older people unnerved by rare side effects associated with mRNA jabs from Pfizer...
...Additional reporting by Oliver Barnes in New York...
...The BioNTech/Pfizer vaccine was 95 per cent against the original virus strain....
...Two doses of the BioNTech/Pfizer vaccine provide 70 per cent protection against being admitted to hospital with the Omicron coronavirus variant, according to the first real-world analysis of protection against...
...However, Ugur Sahin, head of BioNTech, who developed the vaccine now produced by Pfizer, struck a more positive note....
...One senior Department of Health insider said: “We’ll be giving Pfizer to those who had AstraZeneca the first time, and AstraZeneca to those who had Pfizer....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Additional reporting by Kiran Stacey in Washington, Oliver Barnes and Sarah Neville in London, Erika Solomon in Berlin, Nikou Asgari in New York, Mehul Srivastava in Jerusalem, and Sam Fleming in Brussels...
...According to Public Health England, both the Oxford/AstraZeneca and BioNTech/Pfizer vaccines are only 33 per cent effective against symptomatic disease after one dose, with efficacy rising steeply after...
...The company’s pipeline had been transformed since the Parisian saw off a takeover bid from Pfizer in 2014....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Mr Greene has also worked on many complex M&A deals, including pharmaceutical company Mylan’s pending $50bn combination with Upjohn, a division of Pfizer....
...Such an expansion, which Amazon itself has not confirmed, would position it as a competitor to booksellers such as Barnes & Noble....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Pfizer, at least, is coping well since its top-selling Lipitor came off patent at the end of last year, although the US drug company may have to run to stand still....
...Amy Schulman, Executive vice-president and general counsel, Pfizer Since setting up the Pfizer Legal Alliance, a flat-fee structure for 19 of the pharmaceutical company’s law firms, Amy Schulman has gone...
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...The anti-tax message in that 1992 decision, Quill v North Dakota, is not as clear-cut as Amazon’s friends let on....
...Deal activity and changes at the top of Pfizer and Kellogg failed to stop US stocks following global markets slightly lower....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Draw your own conclusions, but Spring Design, which launched the Alex on the eve of Barnes & Noble’s Nook, now says it has filed a lawsuit alleging “Barnes & Noble misappropriated trade secrets and violated...
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
International Edition